Media
News
360Dx: Quotient Launching Multimodal, Multiplex Microarray for Transfusion Diagnostics

NEW YORK ─ Microarray test developer Quotient has entered the market for transfusion diagnostic testing with a multiplex, multimodal platform and is eyeing the development of the system for additional diagnostic applications.

Quotient Limited Celebrates World Blood Donor Day 2021

 

 

MosaiQ by Quotient Wins Prestigious Red Dot Design Award

JERSEY, Channel Islands,12 April 2021 (GLOBE NEWSWIRE) --Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the company has been recognized with a 2021 Red Dot Product Design Award for the full MosaiQ™ by Quotient system. 

Quotient Virtual Tour - Edinburgh, UK

Quotient Limited Wins 2021 BIG Innovation Award

JERSEY, Channel Islands, 12 January 2021(GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has been named a winner in the prestigious 2021 BIG Innovation Awards presented by the Business Intelligence Group.

Quotient Virtual Tour - Eysins, Switzerland

MosaiQ at Bloodworks Northwest Seattle, WA

Take an insider look at how our MosaiQ instrument is used at Bloodworks Northwest, and hear what a Bloodworks technologist and a donor have to say about our technology: 

Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody Test

JERSEY, Channel Islands, 28 September 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland, today announced that on September 25, 2020, the U.S.

Quotient Limited to Publish Quarterly Investor Presentation

JERSEY, Channel Islands, August 4, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today published the latest investor presentation associated with the earnings call for fiscal quarter ended June 30, 2020.

Quotient Limited Reports First Quarter Fiscal 2021 Results and Business Update

•    Significant progress in three targeted areas of MosaiQ development – COVID-19 antibody test, potential new applications, and transfusion diagnostics 
•    Ten commercial placements of MosaiQ platform in Europe and the US